Αρχική World News FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer World News FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer Από Ogkologos - 7 Ιανουαρίου, 2026 506 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLITUDE study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR 5 ways cancer can impact sexual wellbeing 17 Μαΐου, 2023 Prize winning early detection research 7 Οκτωβρίου, 2021 EMA Issues Direct Healthcare Professional Communications for Crizotinib-Related Vision Disorders in... 24 Ιουνίου, 2022 3…2…1…Countdown to Medicare Open Enrollment 12 Οκτωβρίου, 2023 Φόρτωση περισσοτέρων HOT NEWS Baby Boy Can’t Stop Smiling After Surgery Allows Him To See... One in Five of Older Patients with EBC Treated in a... EMA Recommends Extension of Indications for Blinatumomab Severe Immune-Related Gastroenterocolitis Described After in Utero Exposure to Pembrolizumab